Uterine and Endometrial Volume in PCOS and HPOD

Anovulation Clinical Trial

Official title:

Ultrasound Assessment of Uterine and Endometrium Volume in Women With PCOS and HPOD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06211608
• Other study ID #: 118.6120.53.2023
• Status: Recruiting
• Start date: January 5, 2024
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2024
• Source: Jagiellonian University
• Contact: Iwona Gawron, PhD, MD
• Phone: +48 12 4248551
• Email: iwona.gawron[@]uj.edu.pl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Group II causes of anovulation according to the World Health Organization include polycystic ovary syndrome (PCOS) and the less common dysfunction of the hypothalamic-pituitary-ovarian axis (HPOD). Assessment of ovarian volume, number and morphology of ovarian follicles is essential in the diagnosis of menstrual disorders, including PCOS and HPOD. However, the uterus is a target organ for steroid hormones, and the assessment of uterine size and endometrial morphology may also be of clinical importance. While ultrasonographic features of the ovaries in PCOS have been described and constitute one of the diagnostic criteria for the syndrome (Rotterdam criteria), there is little data on uterine volume in women with PCOS and HPOD. The aim is to compare ultrasound i) uterine volume and ii) endometrial volume among women with PCOS and women with HPOD.

Description:

Group II causes of anovulation according to the World Health Organization include polycystic ovary syndrome (PCOS) and the less common dysfunction of the hypothalamic-pituitary-ovarian axis (HPOD). The exact etiology of both entities is unknown. The diagnosis of PCOS requires meeting the Rotterdam criteria. HPOD, in turn, is considered a functional disorder of the axis, related to lifestyle factors, and the diagnosis is made after excluding identifiable causes of ovulation disorders. Assessment of ovarian volume, number and morphology of ovarian follicles is essential in the diagnosis of menstrual disorders, including PCOS and HPOD. However, the uterus is a target organ for steroid hormones, and the assessment of uterine size and endometrial morphology may also be of clinical importance. The dimensions and volume of the uterus and endometrium may influence the clinical pregnancy rate in women undergoing assisted reproductive technologies. Both too small and too large sizes and volumes of the uterus may reduce the rate of clinical pregnancies. Too small dimensions may result from hypoestrogenism, while excessive size may be the result of estrogen-progesterone imbalance accompanying PCOS, increased uterine vascularity, as well as estrogen-dependent changes in the uterine myometrium, such as adenomyosis. Similarly, too "thin" endometrium and too thick (cystic) endometrium may reduce the receptivity of the endometrium. While ultrasonographic features of the ovaries in PCOS have been described and constitute one of the diagnostic criteria for the syndrome (Rotterdam criteria), there is little data on uterine volume in women with PCOS and HPOD. The aim is to compare ultrasound uterine volume and endometrial volume among women with PCOS and women with HPOD. The volume of the uterus will be determined according to the formula: V = (π/6) × length × width × height (in cm and given in ml). The volume of the endometrium will also be measured according to a similar formula.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 31, 2024
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• age 18-45 years
• no previous diagnosis and treatment due to menstrual disorders or infertility

Exclusion Criteria:

• previous ovarian surgery
• use of drugs that disturb the functions of the hypothalamic-pituitary-ovarian axis
• uterine tumors

Related Conditions & MeSH terms

• Anovulation
• Irregular Menses
• Menstruation Disturbances

Intervention

Diagnostic Test:
• Two-dimensional and three-dimensional ultrasound of the female reproductive organ
Two-dimensional and three-dimensional ultrasound of the female reproductive organ using a Samsung WS80A or Samsung HERA W10 ultrasound device with a transvaginal or transabdominal transducer

Locations

Country	Name	City	State
Poland	Jagiellonian University Medical College	Krakow

Sponsors (1)

Lead Sponsor	Collaborator
Jagiellonian University

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Uterine volume	Comparison of uterine volume in ml calculated using the presented formula in both arms of the study	12 months
Primary	Endometrium volume	Comparison of endometrial volume in ml calculated using the presented formula in both arms of the study	12 months